*In patients ≥ 75 years of age, Effient is
generally not recommended, because of the increased risk of fatal and
intracranial bleeding and uncertain benefit, except in high-risk situations
(patients with diabetes or a history of prior MI) where its effect appears to
be greater and its use may be considered